Back to Atlas
APotentially durableResearch-only / high verification need
CMP-0067
Investigational/discontinued oncology
Luminespib / AUY922
Senolytic / HSP90
Senescent-cell survival pathway disruption in models
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Small molecule
- Primary mechanism
- HSP90 inhibition
- Primary market use
- Senolytic / oncology research
Pharmacology
- Molecular weight (Da)
- 465.51
- Oral bioavailability
- N/A; IV clinical development
- Half-life
- ~2-4 h
- Route tags
- Route-dependent / verify
- Evidence level
- Clinical/Preclinical
- Clinical status
- Investigational/discontinued oncology
- Value-for-money score
- 2 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
HSP90 inhibitor; value limited by oncology toxicity profile